Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Espinosa, Diego A; Gutierrez, Gabriel M; Rojas-López, Maricarmen et al. (2015) Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies. J Infect Dis 212:1111-9
Ord, Rosalynn L; Rodriguez, Marilis; Lobo, Cheryl A (2015) Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design. Hum Vaccin Immunother 11:1465-73
Ord, Rosalynn L; Caldeira, Jerri C; Rodriguez, Marilis et al. (2014) A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malar J 13:326
Creech, C Buddy; Dekker, Cornelia L; Ho, Dora et al. (2013) Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother 9:2548-57
Ord, Rosalynn Louise; Rodriguez, Marilis; Yamasaki, Tsutomu et al. (2012) Targeting sialic acid dependent and independent pathways of invasion in Plasmodium falciparum. PLoS One 7:e30251
Graham, Barney S; McElrath, M Juliana; Keefer, Michael C et al. (2010) Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 5:e11995
Gilbert, P B; Chiu, Y-L; Allen, M et al. (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-47
Wright, Peter F; Kozlowski, Pamela A; Rybczyk, G Kyle et al. (2002) Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 18:1291-300
Evans, T G; McElrath, M J; Matthews, T et al. (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19:2080-91
McElrath, M J; Corey, L; Montefiori, D et al. (2000) A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 16:907-19

Showing the most recent 10 out of 19 publications